Treatment of postoperative gastric cancer with the Fuzheng Huoxue anticancer prescription

Table 1 Comparison of T lymphocyte subgroup levels before and after treatment (mean ± SD)

Groups		n	OKT3 (%)	OKT4 (%)	OKT8 (%)	OKT4/OKT8
Treatment	Before	15	56.10 ± 8.54	41.81 ± 6.18a	45.94 ± 8.45b	0.89 ± 0.19b
	After	20	58.68 ± 9.98	41.89 ± 8.70a	33.52 ± 7.80d	1.47 ± 0.51d
Control	Before	13	61.87 ± 5.01	46.61 ± 6.79	49.21 ± 6.60b	0.94 ± 0.20b
	After	12	56.11 ± 8.50	46.24 ± 6.10	42.22 ± 7.07bd	1.12 ± 0.24
Healthy person		15	61.66 ± 6.42	48.11 ± 8.51	31.02 ± 4.96	1.57 ± 0.32

^aP < 0.05;

^bP < 0.001 as compared with the healthy subjects group; ^cP < 0.05;

^dP < 0.001 as compared with pretreatment.

Table 2 Changes in hypercoagulatory parameters before and after treatment in the two groups (mean ± SD)

Groups		n	AT-III (mg/dl)	FA (%)	β-TG (ng/dl)
Treatment	Before	35	29.9 ± 7.9b	50.4 ± 24.4b	91.0 ± 25.9b
	After	35	38.8 ± 5.5d	102.6 ± 31.6d	62.3 ± 15.1bd
Control	Before	34	32.3 ± 7.2a	57.3 ± 24.6b	87.5 ± 34.2b
	After	34	30.9 ± 8.0b	64.6 ± 26.9b	67.0 ± 42.1bc
Healthy persons			36.4 ± 8.3 (59)	90.3 ± 24.3 (30)	25.0 ± 8.2 (103)

^aP < 0.05,

^bP < 0.01 as compared with healthy subjects;

^cP < 0.05,

^dP < 0.001 as compared with pretreatment. The number of individuals is shown in parentheses.